Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone.
O'Sullivan JM, Norman AR, McCready VR, Flux G, Buffa FM, Johnson B, Coffey J, Cook G, Treleaven J, Horwich A, Huddart RA, Parker CC, Dearnaley DP. O'Sullivan JM, et al. Among authors: mccready vr. Eur J Nucl Med Mol Imaging. 2006 Sep;33(9):1055-61. doi: 10.1007/s00259-005-0010-5. Epub 2006 Mar 30. Eur J Nucl Med Mol Imaging. 2006. PMID: 16572306 Clinical Trial.
High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone.
O'Sullivan JM, McCready VR, Flux G, Norman AR, Buffa FM, Chittenden S, Guy M, Pomeroy K, Cook G, Gadd J, Treleaven J, Al-Deen A, Horwich A, Huddart RA, Dearnaley DP. O'Sullivan JM, et al. Among authors: mccready vr. Br J Cancer. 2002 Jun 5;86(11):1715-20. doi: 10.1038/sj.bjc.6600348. Br J Cancer. 2002. PMID: 12087455 Free PMC article. Clinical Trial.
Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival.
Denis-Bacelar AM, Chittenden SJ, Dearnaley DP, Divoli A, O'Sullivan JM, McCready VR, Johnson B, Du Y, Flux GD. Denis-Bacelar AM, et al. Among authors: mccready vr. Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):620-629. doi: 10.1007/s00259-016-3543-x. Epub 2016 Oct 21. Eur J Nucl Med Mol Imaging. 2017. PMID: 27770145 Free PMC article.
A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer.
Buffa FM, Flux GD, Guy MJ, O'Sullivan JM, McCready VR, Chittenden SJ, Dearnaley DP. Buffa FM, et al. Among authors: mccready vr. Eur J Nucl Med Mol Imaging. 2003 Aug;30(8):1114-24. doi: 10.1007/s00259-003-1197-y. Epub 2003 May 22. Eur J Nucl Med Mol Imaging. 2003. PMID: 12761596 Clinical Trial.
Reply to 'Single high dose versus repeated bone-targeted radionuclide therapy'.
Denis-Bacelar AM, Chittenden SJ, Dearnaley DP, Divoli A, O'Sullivan JM, McCready VR, Johnson B, Du Y, Flux GD. Denis-Bacelar AM, et al. Among authors: mccready vr. Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):515-517. doi: 10.1007/s00259-017-3902-2. Eur J Nucl Med Mol Imaging. 2018. PMID: 29247283 No abstract available.
179 results